Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.15
EPS est.
$-0.14
EPS surprise
-7.14%
1-day move
-5.57%
Est. EPS
$3.70
Est. Rev
$3.9B
Impl. Move
±4.7%
Corvus Pharmaceuticals reported a loss of $0.15 per share, which was below expectations. The stock reacted negatively, dropping 5.57%, likely reflecting investor disappointment over the earnings miss and lack of revenue information. Without guidance or management commentary, uncertainty remains about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | -7.14% |
| Revenue | N/A | N/A | N/A |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.